Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled trial of votoplam in early symptomatic Huntington's disease
MOH_2026-03-29_015738Phase 3Not yet recruiting
- Sponsor
- Novartis
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Huntington disease (HD) comparing Votoplam with Placebo (2 arms). Planned start Mar 2026; status: not yet recruiting.
02
Drugs
votoplam
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on MOH_2026-03-29_015738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-03-29_015738.